HRP20161429T1 - Farmaceutski sastav - Google Patents

Farmaceutski sastav Download PDF

Info

Publication number
HRP20161429T1
HRP20161429T1 HRP20161429TT HRP20161429T HRP20161429T1 HR P20161429 T1 HRP20161429 T1 HR P20161429T1 HR P20161429T T HRP20161429T T HR P20161429TT HR P20161429 T HRP20161429 T HR P20161429T HR P20161429 T1 HRP20161429 T1 HR P20161429T1
Authority
HR
Croatia
Prior art keywords
range
present
mass percent
pharmaceutical composition
oral pharmaceutical
Prior art date
Application number
HRP20161429TT
Other languages
English (en)
Croatian (hr)
Inventor
Barry Howard Carter
Dwayne A. Campbell
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37115487&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20161429(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HRP20161429T1 publication Critical patent/HRP20161429T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20161429TT 2005-04-19 2006-04-18 Farmaceutski sastav HRP20161429T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67280505P 2005-04-19 2005-04-19
EP06750475.3A EP1871347B1 (en) 2005-04-19 2006-04-18 Pharmaceutical composition
PCT/US2006/014447 WO2006113649A1 (en) 2005-04-19 2006-04-18 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
HRP20161429T1 true HRP20161429T1 (hr) 2016-12-16

Family

ID=37115487

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20161429TT HRP20161429T1 (hr) 2005-04-19 2006-04-18 Farmaceutski sastav

Country Status (28)

Country Link
US (3) US8821927B2 (https=)
EP (1) EP1871347B1 (https=)
JP (1) JP5202302B2 (https=)
KR (1) KR101356748B1 (https=)
CN (1) CN101203211B (https=)
AR (1) AR054252A1 (https=)
AU (1) AU2006236423B2 (https=)
BR (1) BRPI0609962B1 (https=)
CA (1) CA2606207C (https=)
CY (1) CY1118179T1 (https=)
DK (1) DK1871347T3 (https=)
EA (1) EA200702253A1 (https=)
ES (1) ES2601503T3 (https=)
HR (1) HRP20161429T1 (https=)
HU (1) HUE030982T2 (https=)
IL (1) IL186336A0 (https=)
LT (1) LT1871347T (https=)
MA (1) MA29404B1 (https=)
MX (1) MX2007013089A (https=)
NO (1) NO20075111L (https=)
NZ (1) NZ562223A (https=)
PE (1) PE20061430A1 (https=)
PL (1) PL1871347T3 (https=)
PT (1) PT1871347T (https=)
SI (1) SI1871347T1 (https=)
TW (1) TW200716204A (https=)
WO (1) WO2006113649A1 (https=)
ZA (1) ZA200708705B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2606207C (en) * 2005-04-19 2014-11-18 Smithkline Beecham (Cork) Limited Pharmaceutical composition
WO2009137714A2 (en) * 2008-05-07 2009-11-12 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
EP2158912A1 (en) * 2008-08-25 2010-03-03 Ratiopharm GmbH Pharmaceutical composition comprising N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
EP2158913A1 (en) * 2008-08-25 2010-03-03 Ratiopharm GmbH Pharmaceutical composition comprising N-[3-chhloro-4-[(3-fluorophenyl)methoxy]phenyl]6-(5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
WO2010099150A1 (en) * 2009-02-24 2010-09-02 Smithkline Beecham (Cork) Limited Pharmaceutical tablet and process
WO2011039759A1 (en) * 2009-09-29 2011-04-07 Natco Pharma Limited A new process for the preparation of lapatinib and its pharmaceutically acceptable salts
ES2530755T3 (es) 2010-05-21 2015-03-05 Glaxosmithkline Llc Terapia de combinación para el tratamiento del cáncer
JP2013526578A (ja) 2010-05-21 2013-06-24 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 組合せ
BR112013002511A2 (pt) 2010-08-03 2017-06-27 Altherx Inc combinações de agonistas de receptores adrenérgicos beta - 3 e antagonistas receptores muscarínicos para tratamento da bexica hiperativa
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
ES2635620T3 (es) * 2013-02-19 2017-10-04 Hexal Ag Composición farmacéutica que comprende n-[3-cloro-4-(3-fluorobenciloxi)fenil]-6-[5({[2-(metilsulfonil)etil]amino} metil)-2-furil]quinazolin-4-amina o una sal, solvato o sal solvatada farmacéuticamente aceptables de la misma
WO2014170910A1 (en) 2013-04-04 2014-10-23 Natco Pharma Limited Process for the preparation of lapatinib
US9636340B2 (en) 2013-11-12 2017-05-02 Ayyappan K. Rajasekaran Kinase inhibitors
CN107205964A (zh) 2014-12-03 2017-09-26 威力塞帕特治疗股份有限公司 使用调节释放索拉贝隆用于下尿路症状的组合物和方法
CN106389373B (zh) * 2015-07-29 2019-07-02 四川科伦药物研究院有限公司 一种二甲苯磺酸拉帕替尼片剂及其制备方法
CN106511289A (zh) * 2015-09-10 2017-03-22 湖北生物医药产业技术研究院有限公司 甲苯磺酸拉帕替尼片剂及其制备方法
CN108290824B (zh) 2015-10-23 2022-03-11 B3Ar治疗股份有限公司 索拉贝隆两性离子及其应用
EP4725489A2 (en) 2019-08-02 2026-04-15 OneHealthCompany, Inc. Treatment of canine cancers

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506248A (en) * 1993-08-02 1996-04-09 Bristol-Myers Squibb Company Pharmaceutical compositions having good dissolution properties
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
RU2205831C2 (ru) 1997-04-25 2003-06-10 Янссен Фармацевтика Н.В. Хиназолиноны, ингибирующие фарнезилтрансферазу
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
PL204958B1 (pl) * 2000-06-30 2010-02-26 Glaxo Group Ltd Ditosylany związków chinazolinowych, środek farmaceutyczny i zastosowanie tych związków
DE60203260T2 (de) 2001-01-16 2006-02-02 Glaxo Group Ltd., Greenford Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs
AU2003221684A1 (en) 2002-04-08 2003-10-27 Smithkline Beecham Corporation Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor
AU2003235470A1 (en) * 2002-06-19 2004-01-06 Smithkline Beecham Corporation Predictive markers in cancer therapy
CA2606207C (en) * 2005-04-19 2014-11-18 Smithkline Beecham (Cork) Limited Pharmaceutical composition

Also Published As

Publication number Publication date
CN101203211A (zh) 2008-06-18
ES2601503T3 (es) 2017-02-15
EP1871347B1 (en) 2016-08-03
KR101356748B1 (ko) 2014-02-06
AU2006236423A1 (en) 2006-10-26
PL1871347T3 (pl) 2017-04-28
US20160143909A1 (en) 2016-05-26
WO2006113649A1 (en) 2006-10-26
EA200702253A1 (ru) 2008-04-28
NZ562223A (en) 2010-01-29
SI1871347T1 (sl) 2016-11-30
EP1871347A4 (en) 2012-10-31
US20080206330A1 (en) 2008-08-28
BRPI0609962A2 (pt) 2011-10-11
PT1871347T (pt) 2016-11-10
IL186336A0 (en) 2008-01-20
KR20080005557A (ko) 2008-01-14
CN101203211B (zh) 2012-08-08
EP1871347A1 (en) 2008-01-02
LT1871347T (lt) 2016-11-10
US8821927B2 (en) 2014-09-02
AR054252A1 (es) 2007-06-13
CY1118179T1 (el) 2017-06-28
MA29404B1 (fr) 2008-04-01
NO20075111L (no) 2007-11-16
CA2606207C (en) 2014-11-18
ZA200708705B (en) 2009-12-30
PE20061430A1 (es) 2007-01-25
AU2006236423B2 (en) 2009-12-10
TW200716204A (en) 2007-05-01
JP2008536931A (ja) 2008-09-11
US20140335177A1 (en) 2014-11-13
CA2606207A1 (en) 2006-10-26
DK1871347T3 (en) 2016-11-28
JP5202302B2 (ja) 2013-06-05
BRPI0609962B1 (pt) 2022-01-18
MX2007013089A (es) 2008-01-14
HUE030982T2 (en) 2017-06-28

Similar Documents

Publication Publication Date Title
HRP20161429T1 (hr) Farmaceutski sastav
ES2655435T3 (es) Formulación de disolución rápida de cinacalcet
RU2009127302A (ru) Способ изготовления твердого, орально применимого фармацевтического состава
JP2008536931A5 (https=)
JP2005520796A5 (https=)
HRP20211862T1 (hr) Pripravci za i postupci liječenja anemije
FI2049506T4 (fi) Lääkkeellisten aineiden farmakokineettisten ominaisuuksien modulaattorit
HRP20241461T1 (hr) Aprocitentan za uporabu u liječenju hipertenzije i povezanih bolesti u kombinaciji s valsartanom
BG105061A (bg) Ентерично покрит фармацевтичен състав и метод за получаване
NO20084065L (no) Hurtig frigivelses paracetamol tabletter
HRP20240564T1 (hr) Novi farmaceutski sastav
HRP20120068T1 (hr) Formulacija tablete s odgođenim otpuštanjem koja sadrži pramipeksol ili njegovu farmaceutski prihvatljivu sol
ME02695B (me) Hinazolinoni kao inhibitori humane fosfatidilonozitol 3- delta kinaze
NO20052860L (no) Farmasoytiske pelletter omfattende tamsulosin og en fremgangsmate for fremstilling av samme
CA2406373A1 (en) Controlled release paracetamol composition
RU2011152105A (ru) Составы таблеток 3-цианохинолина и их применение
CY1111939T1 (el) Φαρμακευτικο στερεο παρασκευασμα που περιλαμβανει βενζαζεπινες και μεθοδος παρασκευης αυτου
ATE533476T1 (de) Komprimierte pharmazeutische zusammensetzung mit beschichteten pellets und direktes kompressionsgemisch und herstellungsverfahren dafür
EA200000487A1 (ru) Композиция пролонгированного высвобождения
JP2004532828A5 (https=)
ATE359771T1 (de) Pellets mit venlafaxin-hydrochlorid
JP2019504024A5 (https=)
JP2008515980A5 (https=)
JP2011516544A5 (https=)
JP2010521437A5 (https=)